510(k) device
Rubicon Prothrombin Time Monitoring System
Lifescan, Inc. · Test, Time, Prothrombin (GJS, Class II) · First FDA decision May 15, 2001, newest May 15, 2001Anemia, clotting and blood disordersStroke prevention in atrial fibrillation
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "Rubicon"
MAUDE reports
130
Brand "Rubicon", since 2015
PubMed studies
381
Mentioning "Rubicon"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Rubicon Prothrombin Time Monitoring System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K001699 · Decided May 15, 2001 · 347 days after receipt
Device type: Test, Time, Prothrombin (GJS) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Home Prothrombin Time/International Normalized Ratio (PT/INR) Monitoring for Anticoagulation ManagementNational determinationOn the books190.11Updated Nov 4, 2026
- Prothrombin Time (PT)National determinationOn the books190.17Updated Oct 1, 2026
- Prothrombin Time (INR) Monitor for Home Anticoagulation ManagementNational analysisReview closedCAG-00087RUpdated Sep 21, 2026
- Prothrombin Time and Partial Thromboplastin Time (Revision of ICD-9-CM Codes for Swelling of Limb)Coding analysisReview closedCAG-00201NUpdated Sep 15, 2026
- Prothrombin Time and Partial Thromboplastin Time (Revision of ICD-9-CM Codes for Pre-operative Examinations)Coding analysisReview closedCAG-00184NUpdated Sep 15, 2026
- Prothrombin Time and Fecal Occult Blood (Revision of ICD-9-CM Codes for Injury to Gastrointestinal Tract)Coding analysisReview closedCAG-00187NUpdated Sep 15, 2026
- Prothrombin Time (PT) NCD 190.17 (Addition of ICD-9-CM diagnosis code 197.7 Secondary Malignant Neoplasm of Liver)Coding analysisReview closedCAG-00404NUpdated Sep 15, 2026
- Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) tests (Removal of Unspecified Joint Replacements)Coding analysisReview closedCAG-00246NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Rubicon", any status and sponsor, newest update first.
No registered device study names "Rubicon".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Rubicon", and for the whole product code for context.
This brand
130 reports: 100 malfunction, 30 injury, 0 death
Whole product code GJS
12,207 reports: 11,507 malfunction, 644 injury, 34 death
Newest reports for this brand
- Rubicon 35Injury
2124215-2026-39109 · Received Jul 21, 2026 · Event dated Jun 23, 2026
Device type: Catheter, Percutaneous (DQY)
Device problem as coded: Entrapment of Device; Fracture
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- RUBICON 14Malfunction
2124215-2026-28207 · Received May 26, 2026 · Event dated Apr 28, 2026
Device type: Catheter, Percutaneous (DQY)
Device problem as coded: Fracture; Adverse Event Without Identified Device or Use Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- RUBICON 35Malfunction
2124215-2026-17256 · Received Mar 30, 2026 · Event dated Mar 2, 2026
Device type: Catheter, Percutaneous (DQY)
Device problem as coded: Material Puncture/Hole; Deformation Due to Compressive Stress
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Rubicon"[tiab]. The summary above synthesizes these.
- A RAB7A phosphoswitch coordinates Rubicon Homology protein regulation of Parkin-dependent mitophagy.
Tudorica DA, Basak B, Puerta Cordova AS, et al. · J Cell Biol · 2024Research Support, Non-U.S. Gov't
- The Rubicon-WIPI axis regulates exosome biogenesis during ageing.
Yanagawa K, Kuma A, Hamasaki M, et al. · Nat Cell Biol · 2024
- Rubicon: LC3-associated phagocytosis and beyond.
Wong SW, Sil P, Martinez J · FEBS J · 2018Review
- Rubicon Genomics, Inc.
Langmore JP · Pharmacogenomics · 2002
- Acetylation in the regulation of autophagy.
Xu Y, Wan W · Autophagy · 2023Review, Research Support, Non-U.S. Gov't
- METTL3-m6A-Rubicon axis inhibits autophagy in nonalcoholic fatty liver disease.
Peng Z, Gong Y, Wang X, et al. · Mol Ther · 2022Research Support, Non-U.S. Gov't
- Rubicon in Metabolic Diseases and Ageing.
Minami S, Nakamura S, Yoshimori T · Front Cell Dev Biol · 2021Review
- Metabolic effects of RUBCN/Rubicon deficiency in kidney proximal tubular epithelial cells.
Matsuda J, Takahashi A, Takabatake Y, et al. · Autophagy · 2020Research Support, Non-U.S. Gov't
- Lipid Nanoparticle-Mediated Delivery of CRISPR-Cas9 Against Rubicon Ameliorates NAFLD by Modulating CD36 Along with Glycerophospholipid Metabolism.
Bai Y, Nan Y, Wu T, et al. · Adv Sci (Weinh) · 2024Research Support, Non-U.S. Gov't
- Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer.
Li W, Zhou C, Yu L, et al. · Autophagy · 2024Research Support, Non-U.S. Gov't
- Commentary: Crossing the Rubicon.
Ebright MI · J Thorac Cardiovasc Surg · 2020Editorial, Comment
- Exosome regulation by Rubicon in ageing.
Zhen Y, Stenmark H · Nat Cell Biol · 2024News
Other devices of this type
Also filed under product code GJS.
- microINR SystemIline Microsystems, S.L. · 510(k) 2025
- CoaguChek XS Plus SystemRoche Diagnostics · 510(k) 2025
- Coag-Sense Prothrombin (PT) / INR Monitoring System for Patient Self-TestingCoagusense, Inc. · 510(k) 2022
- CoaguChek XS Pro SystemRoche Diagnostics · 510(k) 2018
- Hemosil Recombiplastin 2G (8 Ml Vial)Instrumentation Laboratory CO · 510(k) 2014
- Coaguchek Xs SystemRoche Diagnostics Corp. · 510(k) 2007
- Xprecia Prime Coagulation SystemUniversal Biosensors Pty, Ltd. · 510(k) 2024
- i-STAT PTplus Cartridge with the i-STAT 1 SystemAbbott Laboratories · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.